share_log

EF Hutton Initiates Coverage On TCR2 Therapeutics With Hold Rating, Announces Price Target of $2

EF Hutton Initiates Coverage On TCR2 Therapeutics With Hold Rating, Announces Price Target of $2

EF Hutton以Hold评级启动对TCR2治疗的覆盖,宣布目标价为2美元
Benzinga Real-time News ·  2023/01/05 04:33

EF Hutton analyst Tony Butler initiates coverage on TCR2 Therapeutics (NASDAQ:TCRR) with a Hold rating and announces Price Target of $2.

EF Hutton分析师Tony·巴特勒以持有评级启动对TCR2治疗公司(纳斯达克:TCRR)的覆盖,并宣布目标价为2美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发